Evidence map›Paper›PMID 42606710›Full record

ReviewMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026

Dual-target carbonic anhydrase inhibitors in cancer therapy: progress, challenges, and opportunities.

Meizhen Luo, Yong Wang, Yinmei Xia, Qin-Min Wang, Jifa Zhang, Lianhai Shan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Meizhen Luo *School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China.
Yong Wang *School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China.
Yinmei Xia *School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China.
Qin-Min WangSchool of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China.
Jifa ZhangSchool of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China. zjf298257@163.com.
Lianhai ShanSchool of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China. mas3330@swjtu.edu.cn.

Funding

the National Natural Science Foundation of China 22377084the Open Project of Individualized Drug Therapy Key Laboratory of Sichuan Province 2024YB01the Support Program of Science & Technology Department of Sichuan Provincial 2025ZNSFSC0691
6 · The paper itself

Abstract

Carbonic anhydrases (CA) are metalloenzymes that mediate diverse physiological and pathological processes, including pH, metabolism, and electrolyte balance, making them key therapeutic targets. Although numerous carbonic anhydrase inhibitors are clinically used for glaucoma, mountain sickness, hypoxic tumors and epilepsy, their efficacy is often limited by systemic toxicity, drug resistance, and poor activity against multifactorial diseases. Multi-target combination therapy, particularly via dual-target agents, offers a promising strategy to overcome these hurdles. Given the synergistic relationships between CA and epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR) and histone deacetylase (HDAC), among other common drug targets, dual-target carbonic anhydrase inhibitors (CAIs) hold great potential to circumvent current limitations and enhance treatment outcomes. This review summarizes recent progress in dual-target CAIs, emphasizing design strategies, structure-activity relationships (SAR), and translational challenges, and provides a theoretical foundation and innovative perspectives for next-generation CA-directed therapies.

Indexed as

Antineoplastic AgentsCarbonic Anhydrase InhibitorsCarbonic AnhydrasesNeoplasmsAnimalsDrug DesignHumansStructure-Activity RelationshipAntineoplastic AgentsCarbonic Anhydrase InhibitorsCarbonic AnhydrasesCACAI Dual inhibitorsDrug designSmall molecule drugs

Identifiers

PMID42606710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.